Medical physics

Profound Medical Announces Second Quarter 2020 Financial Results

Thursday, August 6, 2020 - 9:02pm

TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (MRI), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2020, and provided an update on its operations.

Key Points: 
  • TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (MRI), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2020, and provided an update on its operations.
  • On April 3, 2020, Profound launched a TULSA procedure website, www.tulsaprocedure.com , as a resource for patients with prostate disease.
  • Second quarter 2020 revenue increased approximately 148% from $574,109 in the same three-month period a year ago.
  • Profound Medical is pleased to invite all interested parties to participate in a conference call today, August 6, 2020, at 4:30 pm ET during which time the results will be discussed.

Radiotherapy Market to Cross $17,194.4 Million Revenue by 2030 Says P&S Intelligence

Thursday, August 6, 2020 - 1:30pm

Additionally, the American Institute of Cancer Research says that by 2030, around 25 million cases will be diagnosed every year.

Key Points: 
  • Additionally, the American Institute of Cancer Research says that by 2030, around 25 million cases will be diagnosed every year.
  • Due to the coronavirus pandemic, the radiotherapy market is witnessing subdued growth, as the focus of the healthcare fraternity has shifted from chronic diseases to mitigating the COVID-19 spread.
  • The external beam category, on the basis of type, held the largest share in the radiotherapy market in the past.
  • During the next decade, the fastest growth in the radiotherapy market would be witnessed by the hospitals division, under the end-user segment.

Apex Physics Partners Announces Major Expansion of its Therapy Physics Capability Through Partnership With Alyzen Medical Physics

Thursday, August 6, 2020 - 12:57pm

TOWSON, Md., Aug. 6, 2020 /PRNewswire/ --Apex Physics Partners (APP), a leading medical physics business services support organization, is proud to announce a new partnership withAlyzen Medical Physics, a leader in therapy medical physics services.

Key Points: 
  • TOWSON, Md., Aug. 6, 2020 /PRNewswire/ --Apex Physics Partners (APP), a leading medical physics business services support organization, is proud to announce a new partnership withAlyzen Medical Physics, a leader in therapy medical physics services.
  • The partnership with Alyzen Medical Physics (Alyzen) represents the sixth transaction for Apex Physics Partners since inception and the third transaction within the past 15 months in partnership with Blue Sea Capital.
  • Alyzen has provided therapy medical physics services to health care providers in its home market and across the country for more than 25 years.
  • The addition of Alyzen Medical Physics brings the rapidly growing Apex Physics Partners team to 114 members (up from 16 in 2014).

Carestream Introduces New DRX-Compass X-ray System

Thursday, August 6, 2020 - 1:30pm

Carestream Health has launched its DRX-Compass X-ray System for mid-tier hospitals and medical imaging centers worldwide.

Key Points: 
  • Carestream Health has launched its DRX-Compass X-ray System for mid-tier hospitals and medical imaging centers worldwide.
  • The system offers a flexible and scalable approach to digital imaging with an eye to the future, while increasing workflow efficiency and reducing costs.
  • No matter where they are today, we can build on their system, helping them navigate for where theyll be tomorrow, said Steve Romocki, Worldwide Product Line Manager for Radiology Systems at Carestream.
  • The CARESTREAM DRX-Compass X-ray System is an upgrade-friendly unit that mitigates technology obsolescence with a set of advanced features and options.

TAE Life Sciences to Present at Solebury Trout Summer 2020 Private Company Showcase

Thursday, August 6, 2020 - 12:00pm

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), today announced that Bruce Bauer, Chief Executive Officer, will present a corporate overview at the Summer 2020 Private Company Showcase, hosted by Solebury Trout, on August 10, 2020.

Key Points: 
  • TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), today announced that Bruce Bauer, Chief Executive Officer, will present a corporate overview at the Summer 2020 Private Company Showcase, hosted by Solebury Trout, on August 10, 2020.
  • TAE Life Sciences (TLS) is a privately-held biotechnology company committed to developing a new biologically-targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).
  • TLSs drug and device are currently in development and have not been approved for sale.
  • More information about TAE Life Sciences is available at www.taelifesciences.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005246/en/

RadNet and Hologic Announce Collaboration to Advance the Development of Artificial Intelligence Tools in Breast Health

Thursday, August 6, 2020 - 11:00am

We are energized by the opportunities this transformative collaboration with RadNet creates for patients and clinicians alike.

Key Points: 
  • We are energized by the opportunities this transformative collaboration with RadNet creates for patients and clinicians alike.
  • As part of its collaboration with Hologic, RadNet intends to upgrade its entire fleet of Hologic mammography systems to feature Hologics 3DQuorum imaging technology, powered by Genius AI.
  • As Hologic and RadNet share their respective capabilities and tools, greater efficiency and accuracy can be achieved by our radiologists.
  • Much like RadNet, Hologic is a highly innovative company and market leader in breast health, said Howard Berger, MD, RadNets Chairman and CEO.

RSNA, ACR and AAPM to Develop Massive Open-Source COVID-19 Medical Image Database through NIBIB contract with the University of Chicago

Wednesday, August 5, 2020 - 6:45pm

"The MIDRC database will provide a critical tool to help the medical imaging community, doctors and scientists better understand COVID-19 and its biological effects on humans.

Key Points: 
  • "The MIDRC database will provide a critical tool to help the medical imaging community, doctors and scientists better understand COVID-19 and its biological effects on humans.
  • This knowledge, and the technological advancements the registry can enable, will ultimately help providers save lives," said Etta Pisano, MD, ACR chief research officer.
  • The mission of the AAPM is to advance medicine through excellence in the science, education and professional practice of medical physics.
  • Currently, the AAPM represents over 9,000 medical physicists in over 96 countries.

Center for Diagnostic Imaging Restructures Leadership Team

Wednesday, August 5, 2020 - 8:00pm

MINNEAPOLIS, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Center for Diagnostic Imaging (CDI), one of the nations leading outpatient diagnostic imaging providers, has announced a restructure of its senior leadership team to meet growing demand and expansion of its industry-leading diagnostic imaging platform.

Key Points: 
  • MINNEAPOLIS, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Center for Diagnostic Imaging (CDI), one of the nations leading outpatient diagnostic imaging providers, has announced a restructure of its senior leadership team to meet growing demand and expansion of its industry-leading diagnostic imaging platform.
  • Cherney has been a part of CDIs operational leadership team for more than 10 years, most recently as a SVP/GM of Operations.
  • Prior to that, he was a General Manager for GEs diagnostic imaging business in the U.S.
  • About Center for Diagnostic Imaging (CDI): CDI is one of the nation's leading providers of high-quality diagnostic imaging and interventional radiology services through its network of imaging centers, ambulatory surgery centers, and mobile imaging solutions.

FDA Clears SOMATOM On.site from Siemens Healthineers For CT Head Exams at Patient’s Bedside

Wednesday, August 5, 2020 - 3:00pm

The Food and Drug Administration (FDA) has cleared the SOMATOM On.site, a mobile head computed tomography (CT) scanner from Siemens Healthineers that enables a critically ill patient to receive CT head imaging in the intensive care unit (ICU) while remaining in bed.

Key Points: 
  • The Food and Drug Administration (FDA) has cleared the SOMATOM On.site, a mobile head computed tomography (CT) scanner from Siemens Healthineers that enables a critically ill patient to receive CT head imaging in the intensive care unit (ICU) while remaining in bed.
  • Performing a CT head examination at the patients bedside can eliminate costly transports to the radiology department, which involve high staffing requirements and potential patient risk.
  • With the SOMATOM On.site, Siemens Healthineers enables reliable and consistent image quality at the point of care, allowing customers to transform care delivery.
  • "The SOMATOM On.site transforms the delivery of care for critically ill patients who require a CT head scan, says Douglas Ryan, Vice President of Computed Tomography at Siemens Healthineers North America.

Vyripharm International, Inc. and the National Yang-Ming University Signed a MOU to Develop VYR-206 as a Novel Diagnostic Approach for Neurological Disorders Outcomes Following Treatments

Wednesday, August 5, 2020 - 1:15pm

The MOU expresses the intent to develop the bio-distribution information and targeting profile of VYR-206 for diagnosis and monitoring treatment outcomes of neurological disorders.

Key Points: 
  • The MOU expresses the intent to develop the bio-distribution information and targeting profile of VYR-206 for diagnosis and monitoring treatment outcomes of neurological disorders.
  • Vyripharms drug platform technology is a personalized medicine application for diagnosis, monitoring and treatment of some infectious diseases, neurological disorders and cancers.
  • Moreover, the platform provides a means for labeling diagnostic and therapeutic agents to allow for tissue specific targeted diagnostic imaging and radiotherapy.
  • We are excited at the prospect of a great collaboration to effectively study these challenging neurological disorders.